IFX-1

BIOLOGICAL4 trials

Conditions

C.Surgical Procedure; CardiacGranulomatosis With Polyangiitis (GPA)Hidradenitis SuppurativaHidradenitis Suppurativa (HS)Microscopic Polyangiitis (MPA)Systemic Inflammatory Response Syndrome

Phase 2

Studying Complement Inhibition in Complex Cardiac Surgery

CompletedNCT02866825

InflaRx GmbHC.Surgical Procedure; Cardiac, Systemic Inflammatory Response Syndrome

Start: 2016-05-31End: 2017-01-31Updated: 2017-02-15

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

CompletedNCT03001622

InflaRx GmbHHidradenitis Suppurativa

Start: 2016-12-31End: 2017-07-31Updated: 2017-09-19

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

CompletedNCT03487276

InflaRx GmbHHidradenitis Suppurativa (HS)

Start: 2018-02-26End: 2020-01-27Updated: 2021-04-08

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

CompletedNCT03895801

InflaRx GmbHGranulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

Start: 2019-04-03End: 2021-06-08Updated: 2022-08-25

Related Papers

Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial.

2026-01-01

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (<scp>IHS4</scp>): A post hoc analysis of the <scp>SUNSHINE</scp> and <scp>SUNRISE</scp> trials

Journal of the European Academy of Dermatology and Venereology2024-10-196 citations

Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?

touchREVIEWS in RMD2022-01-01

IFX-1

Sponsors

Conditions

Phase 2

Related Papers